Gene- and cell-based hybrid treatment has received increased attention in the past decade with continuous refinement. In hybrid therapy, a human MSC loaded with the pacemaker gene hyperpolarization-activated cyclic nucleotide-gated channel 2 (HCN2) is implanted in the myocardium to induce the pace-maker function. The gene encoding transcription factor TBX18 has also been used to engineer phenotypic and functional pacemaker cells from myocardial cells in situ (1,2). Stem cells possess the capacity to differentiate into numerous cellular phenotypes and are readily accessible; therefore, they are considered optimal candidates for cardiac pacing (3,4). Bone mesenchymal stem cells (BMSCs) are a type of adult stem cell that have been widely used as cytoreagents for gene therapy (5).
BMSCs are heterogeneous cells derived from bone marrow cavities, which have various advantages compared with other types of stem cell. Notably, BMSCs are able to differentiate into various cell types in vitro. Based on these characteristics, mesenchymal stem cells can be used to deliver biological pace-maker genes, in order to induce the formation of functional and phenotypic pacemaker cells (6-9).
During cardiogenesis, human T-box transcription factors, including T-Box protein 3 (TBX3), TBX5 and TBX18 serve a prominent role in development of the sinoatrial node (SAN), particularly TBX18, which is a gene necessary for early SAN specification. Mesenchymal progenitor cells that express the TBX18 transcription factor are associated with generation of the SAN, particularly formation of the head region, which not only accounts for ~75% of SAN volume, but also produces pacemaker activity in the early phase of embryonic heart formation (10-12). TBX18 gene knock-out mice exhibit a marked reduction in the SAN head region (13). In addition, a proof-of-concept study successfully converted postnatal rat ventricular myocytes to induced pacemaker cells via TBX18 expression (14). These findings may provide information regarding a novel method for generation of a biological pacemaker.
To the best of our knowledge, direct evidence that indicates the transformation of BMSCs to biological pacemaker cells via the TBX18 transcription factor is currently lacking. In the present study, TBX18 was expressed via adenovirus vectors to identify whether a single transcription factor is sufficient to induce differentiation of phenotypic and functional pace-makers. The present study aimed to provide an increased array of treatment options for gene and cell therapies.
Materials and methods
Adult male Sprague-Dawley rats (n=30; age, 2 months; weight, 160-200 g) were purchased from the Center for Disease Control and Prevention of Hubei Province (Hubei, China). The rats were housed in micro-isolators under specific pathogen-free conditions, in a climate-controlled enrivonment with an ambient temperature of 24°C and a 12:12 h light/ dark cycle. They were fed with standard laboratory chow and given sterilized water. The present study was approved by the Experimental Animal Committee of Wuhan University (Hubei, China). All animals received care in accordance with the guidelines for animal care published by the United States National Institutes of Health (NIH) (Guide for the Care and Use of Laboratory Animals, Department of Health and Human Services, NIH Publication no. 86-23, revised 1985).
Isolation and purification of BMSCs
BMSCs were isolated and cultured as described by Huang et al (15) with some modifications. In addition, all attempts were made to minimize rat suffering. Briefly, following sacrifice, the femurs and tibias of rats were quickly stripped, and muscle and extraossial tissue were trimmed. A 5 ml syringe equipped with complete culture medium [Dulbecco's modified Eagle's medium/nutrient mixture F-12 supplemented with 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 U/ml streptomycin] was inserted into the bone marrow cavity, so as to flush target bone marrow cells into culture dishes, which were cultured in an atmosphere containing 5% CO2 at 37°C. The medium was initially substituted at 48 h and was then changed every 3 days. Once the cells reached 80% confluence, adherent cells were trypsinized with 0.25% trypsin solution and passaged. Cells from passages 3-5 were available for use in the following experiments.
Characterization of BMSCs by flow cytometry
BMSCs within passages 3-5 were harvested by trypsinization, and the detached cells were resuspended in PBS. Subsequently, approximately 1×106 cells were stained with the following antibodies: Alexa Fluor® 647 Hamster Anti-Rat cluster of differentiation (CD)29 (562153, 1:100), phycoerythrin (PE)-Cy™7 Mouse Anti-Rat CD90 (561404, 1:100) and fluorescein isothiocyanate (FITC) Mouse Anti-Rat CD45 (561867, 1:100) (all BD Biosciences, San Jose, CA, USA). Control samples were stained with Alexa Fluor® 647-conjugated hamster immunoglobulin (Ig)M isotype anti-body (562110, 1:100) or PE-Cy™7-conjugated mouse IgG1 isotype antibody (557872, 1:100) and FITC-conjugated mouse IgG1 isotype antibody (550616, 1:100) (all from BD Biosciences). Whole incubations were performed at 4°C for 20 min. After incubation, the cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences).
Construction and purification of human TBX18 gene adeno-virus vector
pHBAd-MCMV-GFP (HanBio Biotechnology Co., Ltd., Shanghai, China) was digested with BamHI and NotI. The ORF sequence of the human TBX18 gene (GenScript, Nanjing, China) was amplified by polymerase chain reaction (PCR). After enzyme digestion, gel extraction was performed. The digested fragment and vector were ligated to form pHBAd-MCMV-GFP-TBX18, which was then transformed into competent DH5α cells (Tiangen, Beijing, China). Positive clones were identifed by liquid sequencing. Bacteria in liquid in the logarithmic growth phase were incubated at 37°C in LB culture medium with shaking at 300 × g overnight. Large scale preperation of recombinant plasmid was conducted using the Plasmid Midi Preparation kit (Beijing CW Biotech Co., Ltd., Beijing, China). 293 cells (from our laboratory) were transfected with pHBAd-MCMV-GFP-TBX18 and the backbone vector pHBAd-BHG using Lipoflter™ (both from HanBio Biotechnology Co., Ltd.). The supernatant was harvested after virus amplifcation. Ad-GFP and Ad-TBX18 were measured as 1 1010 PFU/ml and were preserved at −80°C.
Transduction of BMSCs with hTBX18-expressing adeno-virus vector
About (5-8)x105 BMSCs were infected with pHBAd-MCMV-GFP-TBX18 or the pHBAd-MCMV-GFP empty vector at a multiplicity of infection (MOI) of 20, 50, 80 and 100 for 2 h at 37°C, after which the medium was replaced with complete culture medium. Transduction efficiency was estimated according to the proportion of GFP-positive cells. After 24 and 48 h, inverted fluorescence microscopy (IX51; Olympus Corporation, Tokyo, Japan) was used to detect GFP expression. A total of 2 days postinfection, cells were accumulated for evaluation of hTBX18 expression by western blotting and reverse transcription-quantitative PCR (RT-qPCR).
Total RNA isolation and RT-qPCR
Total cellular RNA was extracted from BMSCs using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Subsequently, RT was conducted using the PrimeScript™ RT reagent kit (Takara Biotechnology, Ltd., Dalian, China) in a 20 µl mixture. RT-qPCR was performed using SYBR® Premix Ex Taq™kit (Takara Biotechnology, Ltd.) as follows: 95°C for 1 min followed by 40 cycles of 95°C for 15 sec, 58°C for 20 sec and 72°C for 45 sec and a final extension at 60°C for 10 min. GAPDH was used as a reference gene. The results of RT-qPCR were analyzed using the 2−ΔΔCq method (16). To ensure accuracy, each sample was analyzed ≥3 times. The primers used in this experiment are presented in Table I.
Primer sequences used in the study.
Primer sequences used in the study.
|Gene||Primer sequences (5′-3′)||Accession no.||Size (bp)|
Western blot analysis
The cells were harvested using RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of protein (40 µg) were loaded onto a gel for 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and the seperated proteins were transferred to a nitrocellulose membrane, and were subsequently incubated with primary antibodies overnight at 4°C. Goat-anti-TBX18 polyclonal primary antibody (sc-17869, 1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was applied to detect TBX18 protein expression 48 h post-trans-duction. Rabbit anti-α-actin monoclonal antibody (ab156302, 1:3,000), mouse anti-cardiac troponin I (cTnI) monoclonal antibody (ab19615, 1:1,000), rat anti-hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4) monoclonal antibody (ab32675, 1:500) and rabbit anti-connexin 43 (CX43) polyclonal antibody (ab11370, 1:2,000) (all Abcam, Cambridge, MA, USA) were applied to detect biological pacemaker induction of BMSCs after 1 week of culture. After washing, the membranes were incubated with 1:10,000 horseradish peroxidase (HRP) -rabbit anti-goat (14-13-06), HRP-goat anti-rabbit (074-1506), anti-rat (14-16-06) or anti-mouse IgG (074-1806) (all KPL, Inc., Gaithersburg, MD, USA) secondary antibodies for 30 min at room temperature. Enhanced chemiluminescence detection (ECL; Beyotime Institute of Biotechnology) was then performed. GAPDH was used as a loading control. All western blot analyses were repeated >3 times.
A total of 1 week post-transduction, immunofluorescence staining was performed on cultured cells. Briefly, approximately (5-8)x105 cells grown on glass cover-slips were fixed with 4% paraformaldehyde for 20 min at room temperature. Following permeabilization with 0.1% Triton X-100, cells were incubated overnight with rat anti-HCN4 monoclonal primary antibody (ab32675, 1:50; Abcam) at 4°C and were then incubated with Cy3-labeled goat anti-rat secondary antibody (AS-1111, 1:50; Aspen Biotechnology, Hubei, China) for 50 min at room temperature. Nuclei were also stained with 4′,6-diamidino-2-phenylindole for 5 min. Fluorescent images were acquired using an inverted fluorescent microscopy.
The reported data are expressed as the means ± SD. The statistical signifcance of the differences between two groups was determined using the Student's t-test. Comparisons among 3 groups were made using one-way analysis of variance (ANOVA). A P-value <0.05 was considered to indicate a statistically significant difference.
Morphological characteristics and identification of BMSCs
When initially seeded, BMSCs appeared round in shape. After 48 h, cells became adherent, and exhibited triangular, fusiform or spindle shapes. These colonies fused after 6-8 days of culture; the majority of cultured cells exhibited uniform spindle-like morphology. As the number of passages increased, sub-cultured cells were more purified, homogenous and spindle-like (Fig. 1A and B).
Flow cytometric analysis
To identify BMSC phenotypes, flow cytometry was conducted. The results indicated that BMSCs expressed stromal cell markers CD29 and CD90 (≤99%); however, almost no expression of the hematopoietic marker, CD45, was detected (Fig. 1C). These findings suggested that the cells tested were purified BMSCs.
Transduction of BMSCs with pHBAd-MCMV-GFP-TBX18 or pHBAd-MCMV-GFP
Through continuous attempts, the present study confirmed that the appropriate MOI was 100, which was the lowest adenovirus titer that generated optimal infection efficiency. Post-transduction for 24 h, green fluorescence could be detected under fluorescent microscopy. Under this condition, the transduction efficiency was 97-99% (Fig. 2A and B). The expression levels and high infection efficiency peaked at 48 h and then faded gradually (Fig. 2C and D). These findings confirmed that the plasmids had been successfully transduced into the BMSCs.
Identification of target protein expression by western blotting and RT-qPCR
A total of 48 h after lipofection, transgene expression was examined by RT-qPCR and western blot-ting. The protein expression levels of TBX18 in BMSCs are presented in Fig. 3A; the results indicated that the transduced cells successfully expressed TBX18 protein. The protein expression levels of TBX18 were normalized to GAPDH (Fig. 3B). The results of RT-qPCR detection of TBX18 mRNA, relative to GAPDH, are presented in Fig. 3C. These results indicated that pHBAd-MCMV-GFP-TBX18 was successfully introduced into BMSCs.
Western blotting and reverse transcription-quantitative polymerase chain reaction analysis of target protein and mRNA expression post-transduction. (A) pHBAd-MCMV-GFP-TBX18-transduced BMSCs displayed exogenous TBX18 expression, as determined by western blotting. (B) Protein expression levels of TBX18 were verified in differentiated cells by western blotting. (C) Alterations in the relative mRNA expression levels of TBX18 were compared between the T group and the G and B groups. (D) Quantitative analysis of the mRNA expression levels of α-actin, HCN4 and CX43. (E) Western blotting detected increased α-actin, cTnI and HCN4 protein expression, and reduced CX43 protein expression, in the T group compared with in the G and B groups. ※P<0.05, T group vs. G group; △P<0.05, T group vs. B group. BMSCs, bone mesenchymal stem cells; B, blank group; cTnI, cadiac troponin I; CX43, connexin 43; G, GFP group/empty plasmid group; GFP, green fluorescent protein; HCN4, hyperpolarization-activated cyclic nucleotide-gated channel 4; hTBX18, human TBX18; T, TBX18 group; TBX18, T-box protein 18.
RT-qPCR analysis of genes associated with cardiac pacing in BMSCs
The expression levels of target genes associated with biological pacemaker development were detected in BMSCs infected with pHBAd-MCMV-GFP-TBX18. The genes detected in the present study included α-actin, HCN4 and CX43. As shown in Fig. 3D, the mRNA expression levels of α-actin and HCN4 were significantly increased in BMSCs infected with TBX18 adenovirus (T group) compared with in the empty plasmid group (G group) and the blank group (B group) (P<0.05). Conversely, the expression levels of CX43 were significantly lower in the T group compared with in the G and B groups (P<0.05). No significant differences were detected between the G and B groups.
Western blot analysis of target protein expression
A total of 1 week post-transduction, total proteins were extracted from cells in the T, G and B groups. Western blotting was used to detect the protein expression levels of α-actin, cTnI, HCN4 and CX43. The results indicated that α-actin, cTnI and HCN4 expression levels in the T group were significantly upregulated compared with in the G and B groups (P<0.05). Conversely, CX43 expression was significantly downregulated in the T group compared with in the G and B groups (P<0.05; Fig. 3E). No significant differences were detected between the G and B groups.
Immunocytochemical analysis of BMSCs following transgene induction
After being cultured for 1 week, some differenti-ated cells developed the biological pacemaker phenotype. As demonstrated in Fig. 4A, TBX18-transduced BMSCs co-expressed HCN4 (red) and GFP (green) in vitro, indicating that the TBX18 adenovirus vector induced biological pacemaker differentiation of BMSCs. However, in the GFP-transduced group HCN4 protein expression (red) was barely detectable (Fig. 4B).
As a consequence of the advanced progress in the field of molecular biology, gene reprogramming techniques have been used in various aspects of biology. BMSCs exhibit numerous differentiative abilities in vivo and in vitro (17,18). Notably, mesenchymal stem cells can inhibit T-cell proliferation, so as to restrain immunoreactivity of the host (19). BMSCs loaded with the biological pacemaker genes HCN4 or HCN2 have been successfully implanted into the myocardium of large animals to induce pacemaker function (20-23).
BMSCs are easy to modify at the genetic level. The present study introduced the TBX18 transcription factor into BMSCs to determine whether this gene is able to accomplish the direct conversion of BMSCs to biological pacemaker cells. TBX18 can not only induce the direct conversion of neonatal rat ventricular myocytes to pacemaker cells, but also produces stable pacemaker activity for ~2 weeks via injection of TBX18 adenovirus in pigs, along with complete heart block (24). These findings suggested that TBX18 may be an optimal candidate gene in the biological pacemaker process. In the present study, on the 7th day of culture, positive results were detected, and the outcomes were evaluated with western blotting, RT-qPCR and immunofluorescence.
To identify whether TBX18 may induce the myocardial phenotype of BMSCs, the cells were incubated with antibodies against cardiomyocyte-associated proteins, including cTnI and α-actin, which are myocardium-specific markers. cTnI is one of three subunits of troponin (cTnI, cTnT and cTnC), which is located in the thin filaments (25). cTnI inhibits the connection between myosin and actin via intracellular Ca2+ to regulate muscle contraction and relaxation; mutations in cTnI result in hypertrophic cardiomyopathy (26). α-actin is known as cardiac structural gene, which is expressed in mouse cardiac tissue during embryogenesis and can provide redundant function (27). In the present study, western blotting and RT-qPCR detected cTnI and α-actin expression in TBX18-transduced BMSCs, which is consistent with the features of the SAN.
Notably, HCN4 expression was detected in the induced cells in the present study. The SAN is located in the right atrium adjacent to the superior vena cava, and is responsible for heartbeat initiation (28). HCN4 is an important HCN isoform, which accounts for >80% of the total amount of HCN mRNA (29,30). Furthermore, HCN4 expression is the most typical characteristic of pace-maker cells. Furthermore, HCN4 expression is the most typical characteristic of pacemaker cells. In the present study, HCN4 expression was detected through western blotting, RT-qPCR and immunofluorescence. The present study demonstrated that the expression levels of cTnI, α-actin and HCN4 were significantly increased in TBX18-transduced cells. However, CX43 expression levels were markedly downregulated in the TBX18-transduced groups compared with in the GFP-transduced and blank groups. These findings were consistent with those of Kapoor et al (31). TBX18 may repress the CX43 promoter directly, further to the transcript and protein levels, other connexins like CX30.2, CX40 and CX45 promotes the slow action potential propagation. The characteristics of the TBX18-transduced BMSCs were similar to the functional features of the SAN, which include slow contractibility and slow-propagating connexins compared with the surrounding myocardium.
For high-efficiency transduction, adenovirus vectors were selected as ideal gene therapy vehicles in the present study. In previous studies, adenovirus vectors have been used for a large amount of transgene therapies, due to their ease of production, high titers, stable inheritance, sufficient transduction efficiency and early peak expression compared with other vectors (32-35). However, adenovirus-mediated gene expression may not last a long period of time; peaking at ~1 week, declining at 3-5 weeks and vanishing at ~10 weeks (36). Consequently, adenovirus vectors are appropriate for temporary applications that have no demand for long-term gene expression. In addition, adenovirus vectors are likely to induce inflammatory and immune responses; therefore, their permanent safety and efficacy remains to be improved.
In conclusion, the present study indicated that expression of the transcription factor TBX18 is capable of initiating differentiation of BMSCs into biological pacemaker cells. This discovery represents a possible therapeutic alternative to electronic devices. However, long-term practice in large animals is required to evaluate the safety prior to application in patients with sinus dysfunction.
Flow cytometry conducted in the present study was supported by Central Laboratory, Renmin Hospital, Wuhan University (Wuhan, China). The present study was supported by the Fundamental Research Funds for the Central Universities of China (grant nos. 2042015kf0229 and 2042014 kf0306).
Rosen MR: Gene therapy and biological pacing. N Engl J Med. 371:1158–1159. 2014. View Article : Google Scholar : PubMed/NCBI
Chauveau S, Brink PR and Cohen IS: Stem cell-based biological pacemakers from proof of principle to therapy: A review. Cytotherapy. 16:873–880. 2014. View Article : Google Scholar : PubMed/NCBI
Cai B, Li J, Wang J, Luo X, Ai J, Liu Y, Wang N, Liang H, Zhang M, Chen N, et al: microRNA-124 regulates cardiomyocyte differentiation of bone marrow-derived mesenchymal stem cells via targeting STAT3 signaling. Stem Cells. 30:1746–1755. 2012. View Article : Google Scholar : PubMed/NCBI
Psaltis PJ, Zannettino AC, Worthley SG and Gronthos S: Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 26:2201–2210. 2008. View Article : Google Scholar : PubMed/NCBI
Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, Houkin K, Matsunaga T and Niitsu Y: Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 96:149–156. 2005. View Article : Google Scholar : PubMed/NCBI
Zhou YF, Yang XJ, Li HX, Han LH and Jiang WP: Mesenchymal stem cells transfected with HCN2 genes by LentiV can be modified to be cardiac pacemaker cells. Med Hypotheses. 69:1093–1097. 2007. View Article : Google Scholar : PubMed/NCBI
Yang XJ, Zhou YF, Li HX, Han LH and Jiang WP: Mesenchymal stem cells as a gene delivery system to create biological pacemaker cells in vitro. J Int Med Res. 36:1049–1055. 2008. View Article : Google Scholar : PubMed/NCBI
Ma J, Zhang C, Huang S, Wang G and Quan X: Use of rats mesenchymal stem cells modified with mHCN2 gene to create biologic pacemakers. J Huazhong Univ Sci Technolog Med Sci. 30:447–452. 2010. View Article : Google Scholar : PubMed/NCBI
Nong Y, Zhang C, Wei L, Zhang Z, Cheng J, Wen L and Song Z: In situ investigation of allografted mouse HCN4 gene-transfected rat bone marrow mesenchymal stromal cells with the use of patch-clamp recording of ventricular slices. Cytotherapy. 15:905–919. 2013. View Article : Google Scholar : PubMed/NCBI
Wiese C, Grieskamp T, Airik R, Mommersteeg MT, Gardiwal A, de Gier-de Vries C, Schuster-Gossler K, Moorman AF, Kispert A and Christoffels VM: Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ Res. 104:388–397. 2009. View Article : Google Scholar
McNally EM and Svensson EC: Setting the pace: Tbx3 and Tbx18 in cardiac conduction system development. Circ Res. 104:285–287. 2009. View Article : Google Scholar : PubMed/NCBI
Cho HC: Pacing the heart with genes: Recent progress in biological pacing. Curr Cardiol Rep. 17:652015. View Article : Google Scholar : PubMed/NCBI
Greulich F, Trowe MO, Leffler A, Stoetzer C, Farin HF and Kispert A: Misexpression of Tbx18 in cardiac chambers of fetal mice interferes with chamber-specific developmental programs but does not induce a pacemaker-like gene signature. J Mol Cell Cardiol. 97:140–149. 2016. View Article : Google Scholar : PubMed/NCBI
Kapoor N, Liang W, Marbán E and Cho HC: Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol. 31:54–62. 2013. View Article : Google Scholar
Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD and Li RK: Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001. View Article : Google Scholar
Karaoz E, Aksoy A, Ayhan S, Sariboyaci AE, Kaymaz F and Kasap M: Characterization of mesenchymal stem cells from rat bone marrow: Ultrastructural properties, differentiation potential and immunophenotypic markers. Histochem Cell Biol. 132:533–546. 2009. View Article : Google Scholar : PubMed/NCBI
Ye NS, Chen J, Luo GA, Zhang RL, Zhao YF and Wang YM: Proteomic profiling of rat bone marrow mesenchymal stem cells induced by 5-azacytidine. Stem Cells Dev. 15:665–676. 2006. View Article : Google Scholar : PubMed/NCBI
Tokcaer-Keskin Z, Akar AR, Ayaloglu-Butun F, Terzioglu-Kara E, Durdu S, Ozyurda U, Ugur M and Akcali KC: Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: A perspective for emergencies. Can J Physiol Pharmacol. 87:143–150. 2009. View Article : Google Scholar : PubMed/NCBI
Potapova I, Plotnikov A, Lu Z, Danilo P Jr, Valiunas V, Qu J, Doronin S, Zuckerman J, Shlapakova IN, Gao J, et al: Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res. 94:952–959. 2004. View Article : Google Scholar : PubMed/NCBI
Plotnikov AN, Shlapakova I, Szabolcs MJ, Danilo P Jr, Lorell BH, Potapova IA, Lu Z, Rosen AB, Mathias RT, Brink PR, et al: Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation. 116:706–713. 2007. View Article : Google Scholar : PubMed/NCBI
Cheng J, Zhang Z, Wei L, Nong Y, Wen L, Qin Y and Song Z: Canine bone marrow mesenchymal stromal cells with lentiviral mHCN4 gene transfer create cardiac pacemakers. Cytotherapy. 14:529–539. 2012. View Article : Google Scholar
Wei L, Nong Y, Boli R, Cheng J, Zhang C, Zhou Y and Song Z: mHCN4 genetically modified canine mesenchymal stem cells provide biological pacemaking function in complete dogs with atrioventricular block. Pacing Clin Electrophysiol. 36:1138–1149. 2013. View Article : Google Scholar
Hu YF, Dawkins JF, Cho HC, Marbán E and Cingolani E: Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med. 6:245ra942014. View Article : Google Scholar : PubMed/NCBI
Takahashi-Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, Ohta M, Lu QW, Sasaguri T and Ohtsuki I: Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 33:2095–2107. 2001. View Article : Google Scholar : PubMed/NCBI
Ruan Z, Zhu L, Yin Y and Chen G: Overexpressing NKx2.5 increases the differentiation of human umbilical cord drived mesenchymal stem cells into cardiomyocyte-like cells. Biomed Pharmacother. 78:110–115. 2016. View Article : Google Scholar : PubMed/NCBI
Xu M, Wani M, Dai YS, Wang J, Yan M, Ayub A and Ashraf M: Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation. 110:2658–2665. 2004. View Article : Google Scholar : PubMed/NCBI
Husse B and Franz WM: Generation of cardiac pacemaker cells by programming and differentiation. Biochim Biophys Acta. 1948–1952.2016:1863PubMed/NCBI
Robinson RB and Siegelbaum SA: Hyperpolarization-activated cation currents: From molecules to physiological function. Annu Rev Physiol. 65:453–480. 2003. View Article : Google Scholar
Verkerk AO and Wilders R: Pacemaker activity of the human sinoatrial node: Effects of HCN4 mutations on the hyperpolarization-activated current. Europace. 16:384–395. 2014. View Article : Google Scholar : PubMed/NCBI
Kapoor N, Galang G, Marbán E and Cho HC: Transcriptional suppression of connexin43 by TBX18 undermines cell-cell electrical coupling in postnatal cardiomyocytes. J Biol Chem. 286:14073–14079. 2011. View Article : Google Scholar : PubMed/NCBI
French BA, Mazur W, Geske RS and Bolli R: Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 90:2414–2424. 1994. View Article : Google Scholar : PubMed/NCBI
Brenner M: Gene transfer by adenovectors. Blood. 94:3965–3967. 1999.PubMed/NCBI
Wright MJ, Wightman LM, Lilley C, de Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS and Marber MS: In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol. 96:227–236. 2001. View Article : Google Scholar : PubMed/NCBI
Li RA: Gene- and cell-based bio-artificial pacemaker: What basic and translational lessons have we learned? Gene Ther. 19:588–595. 2012. View Article : Google Scholar : PubMed/NCBI
ГЛАВА 101 Дэвид Беккер никогда не держал в руках оружия. Сейчас ему пришлось это сделать. Скрюченное тело Халохота темнело на тускло освещенной лестнице Гиральды. Беккер прижал дуло к виску убийцы и осторожно наклонился.